

Sternberg en Apolo schrijven in hun editorial dat MVAC reeds in 1985 werd beschreven, en dat het neoadjuvant gebruik van MVAC in 1988 werd gepubliceerd: ' MVAC is one of the most active chemotherapy regimens for bladder cancer, and so far, we have nothing better .'
1. Sternberg CN, Apolo AB. Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer. J Clin Oncol 2014;epub ahead of print
2. Choueiri TK, Jacobus S, Bellmunt J et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;epub ahead of print
3. Plimack ER, Hoffman-Censits JH, Viterbo R et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer. Results of a multi-center phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014;epub ahead of print